Tags : onvansertib


ViewPoints Interview: Cardiff Oncology’s Mark Erlander Shares Insight on the

In an interview with PharmaShots, Mark Erlander, CEO of Cardiff Oncology shared his views on the data presented at the ASCO-GI Conference, P-Ib results of Onvansertib, what these results meant for the patients with this aggressive type of mCRC, and the company’s other ongoing programs for Onvansertib, including metastatic castration-resistant prostate cancer and AML Shots: […]Read More